/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./
08/10/2022 - 12:41 PM
In the news release, NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022 , issued Aug. 10, 2022 by NRx Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the Conference ID has been updated to 10170239. The complete, corrected release follows:
NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022
--Company to Host Conference Call August 15th, 2022 , at 8:30AM ET ---
RADNOR, Pa. Aug. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report second quarter 2022 financial results prior to the market open on August 15, 2022 . The company will host a conference call and webcast on August 15, 2022 , 8:30AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company's investor relations representative at rsheffield@nrxpharma.com by 4:00 PM Eastern Time on Friday , August 12, 2022.
NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Psychiatry Franchise
Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (844) 826-3033 (U.S.), (412)317-5185 (International) Conference ID: 10170239, or through the webcast link NRx Pharmaceuticals Second Quarter 2022 Earnings Call www.nrxpharma.com .
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience applying innovative science to known molecules to address very high unmet needs and bring improved health to patients. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly , Pfizer, and Novartis as well as major investment banking institutions.
Cautionary Note Regarding Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management.
The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.
CORPORATE CONTACT Molly Cogan Sr. Director, Global Communications mcogan@nrxpharma.com
INVESTOR RELATIONS Tim McCarthy Investor Relations tim@lifesciadvisors.com
https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-second-quarter-2022-results-on-august-15-2022-301603285.html
SOURCE NRx Pharmaceuticals, Inc.
